RUNX1 family platelet disease is a suspected disease in the field of blood tumors, with complex clinical outcomes and often involving multi-system fatigue. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging checks, laboratory checks and pathological biopsies.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Treatment and management of RUNX1 family platelet disease requires individualized development, typically including multidimensional management of prognosis, including drug therapy, rehabilitation, regular follow-up, etc. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many blood tumour diseases that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of RUNX1 family platelet disease. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.